JP2017521370A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521370A5
JP2017521370A5 JP2016569613A JP2016569613A JP2017521370A5 JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5 JP 2016569613 A JP2016569613 A JP 2016569613A JP 2016569613 A JP2016569613 A JP 2016569613A JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5
Authority
JP
Japan
Prior art keywords
concentration
preparation according
lyophilized
nr2b9c
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569613A
Other languages
English (en)
Japanese (ja)
Other versions
JP6707469B2 (ja
JP2017521370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053996 external-priority patent/WO2015181757A1/en
Publication of JP2017521370A publication Critical patent/JP2017521370A/ja
Publication of JP2017521370A5 publication Critical patent/JP2017521370A5/ja
Application granted granted Critical
Publication of JP6707469B2 publication Critical patent/JP6707469B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569613A 2014-05-28 2015-05-28 アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 Expired - Fee Related JP6707469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004144P 2014-05-28 2014-05-28
US62/004,144 2014-05-28
PCT/IB2015/053996 WO2015181757A1 (en) 2014-05-28 2015-05-28 Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020087977A Division JP2020143116A (ja) 2014-05-28 2020-05-20 アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2017521370A JP2017521370A (ja) 2017-08-03
JP2017521370A5 true JP2017521370A5 (https=) 2018-06-21
JP6707469B2 JP6707469B2 (ja) 2020-06-10

Family

ID=54698211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569613A Expired - Fee Related JP6707469B2 (ja) 2014-05-28 2015-05-28 アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
JP2020087977A Pending JP2020143116A (ja) 2014-05-28 2020-05-20 アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020087977A Pending JP2020143116A (ja) 2014-05-28 2020-05-20 アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤

Country Status (5)

Country Link
US (3) US10206878B2 (https=)
EP (1) EP3148568A4 (https=)
JP (2) JP6707469B2 (https=)
CA (1) CA2950392A1 (https=)
WO (1) WO2015181757A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2015181757A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
EP4553432B1 (en) 2023-11-08 2026-04-29 Bachem Holding AG Drying bag and drying system
WO2025099273A1 (en) 2023-11-08 2025-05-15 Bachem Holding Ag Drying bag and drying system

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
JP2009531371A (ja) * 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EP2501408B1 (en) * 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
SG10201502398RA (en) * 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations
ES2655112T3 (es) 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
CN107625958A (zh) * 2011-05-17 2018-01-26 索利吉尼克斯公司 热稳定性疫苗组合物及其制备方法
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
PL2925338T3 (pl) 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2015181757A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Similar Documents

Publication Publication Date Title
JP2017521370A5 (https=)
RU2016150678A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2016520075A5 (https=)
JP2015091902A5 (https=)
ZA201900367B (en) Formulation of a peptide vaccine
BR112017009405A2 (pt) composições antibióticas.
WO2016184576A3 (en) Dry powder composition comprising long-chain rna
EA201890220A1 (ru) Вакцина против rsv
WO2015044337A3 (en) Dry formulations of vaccines that are room temperature stable
JP2013542919A5 (https=)
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
PE20181400A1 (es) Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
IN2012DE00337A (https=)
PH12014501628A1 (en) Stabilized formulations containing anti-ang2 antibodies
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
JP2018528242A5 (https=)
EP4606820A3 (en) Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
HRP20191166T1 (hr) Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
JP2017532343A5 (https=)
UY37394A (es) Métodos para alterar el contenido de aminoácidos en plantas
HRP20211838T1 (hr) Krnji protein vp4 rotavirusa i njegova primjena
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli